Mode
Text Size
Log in / Sign up
Phase 1 N=10 Diagnostic

Diagnosing Natriuretic Peptide Deficiency

Healthy · Lean

Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Jun 2019
Primary outcome: Primary: Changes in NT-proANP From Baseline to 8 Hours — -0.33 nmol/l

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
Dexamethasone (Drug)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Vanderbilt University Medical Center
Primary completion
Jun 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Changes in NT-proANP From Baseline to 8 Hours
-0.33
PRIMARY
Changes in NT-proBNP From Baseline to 8 Hours
18.4
SECONDARY
Changes in NT-proANP
-0.23; 0.17; -0.05
SECONDARY
Changes in NT-proBNP
-5.0; -23.4; -16.9
SECONDARY
BNP (B-type Natriuretic Peptide)
SECONDARY
ANP (Atrial Natriuretic Peptide)

Summary

In this pilot study, the investigators will determine the response of the natriuretic peptide (NP) hormone system after a dose of intravenous dexamethasone (a steroid medication). The goal of the proposed project is to generate preliminary data that will be used to develop power calculations, inform cutoff ranges, and inform the timing of the NP response for larger subsequent studies. Aim: To determine the range of distribution and time course of natriuretic peptide (NP) responses to a single dose of dexamethasone IV 4 mg in healthy lean individuals. Hypothesis: Determination of the NP responses (the range and time course of changes in NP levels) to dexamethasone in 10 healthy individuals will inform the time course and frequency of blood sampling in a definitive prospective study, as well as enable investigators to perform a sample size calculation for a definitive prospective study.

Eligibility Criteria

Inclusion criteria

  • Men and women ages 18-50 years
  • BMI 18.5 to 2 times upper limit of normal
  • Estimated glomerular filtration rate 5.7
  • Abnormal sodium or potassium level
  • Positive pregnancy test, women of child-bearing age not practicing birth control, women who are breastfeeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03035929). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search